

1 **Antibody response after a single dose of BBV152 vaccine negatively correlates**
2 **with pre-existing antibodies and induces a significant but low levels of neutralizing**
3 **antibodies to Omicron variant**

4 **Running title:** Antibody response by BBV152 vaccine

5
6 Suman Das^{1*}, Janmejay Singh^{2*}, Heena Shaman^{2*}, Balwant Singh², Anbalagan
7 Anantharaj², Patil Sharanabasava², Rajesh Pandey³, Rakesh Lodha⁴, Anil Kumar
8 Pandey¹ and Guruprasad R. Medigeshi^{2#}

9 1: Employees State Insurance Corporation Medical College and Hospital, Faridabad,
10 Haryana, INDIA.

11 2: Translational Health Science and Technology Institute, Faridabad, Haryana. INDIA.

12 3: INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute of
13 Genomics and Integrative Biology, Delhi, INDIA.

14 4: All India Institute of Medical Sciences, New Delhi, INDIA.

15

16 *** These authors contributed equally**

17 **# Corresponding author:**

18 Guruprasad R. Medigeshi, PhD

19 Translational Health Science and Technology Institute,

20 P.O. Box # 4, Faridabad-Gurgaon Highway,

21 Faridabad 121001. INDIA.

22 Tel: +91-0129-2876311. Email: gmedigeshi@thsti.res.in

23

24 **ABSTRACT**

25 Most adults in India have received at least one dose of COVID-19 vaccine and also been
26 infected naturally during the pandemic. As immunization of individuals continues under
27 this situation where the virus has attained endemicity, we assessed whether this hybrid
28 immunity is further boosted by a single dose of BBV152, an inactivated SARS-CoV-2
29 vaccine, and, if these antibodies can neutralize SARS-CoV-2 delta and omicron variants.
30 We found that natural infection during the second wave in 2021 led to generation of
31 neutralizing antibodies against other lineages of SARS-CoV-2 including the omicron
32 variant, albeit at a significantly lower level for the latter. A single dose of BBV152 boosted
33 antibody titers against the delta and the omicron variants but the antibody levels remained
34 low for the omicron variant. Boosting of antibodies showed negative correlation with
35 baseline neutralizing antibody titers suggesting anergy of the immune system in
36 individuals with high levels of antibodies.

37

38 **KEYWORDS:** SARS-CoV-2; FRNT; ELISA; RBD; Delta; Omicron

39

40 **INTRODUCTION**

41 Serosurveillance studies have showed that 69% of the Indian population had antibodies
42 for COVID-19 after the second wave¹ and a subsequent serosurvey from Delhi showed
43 seropositivity of over 90%² suggesting that India was/is a heterogenous mix of people
44 with immunity to COVID-19 due to vaccination or natural infection or both after the second
45 wave. As COVID-19 has attained a state of endemicity and majority of the population got
46 vaccinated after the second wave, there have been no studies to measure the impact of
47 pre-existing humoral immunity on subsequent vaccination. As antibody levels wane and
48 the risk of reinfection with the same variant and or a new variant warrants booster
49 vaccination, it is imperative to understand the efficiency of boosting vis-à-vis pre-existing
50 antibody levels. We enrolled subjects who got vaccinated with BBV152 as part of routine
51 vaccination program and assessed the effect of pre-existing antibody levels on boosting
52 after receiving a single dose of vaccine. We found that majority of the individuals had
53 neutralizing antibodies to delta variant and natural infection with delta variant led to
54 generation of neutralizing antibodies against other lineages of SARS-CoV-2 including the
55 omicron variant although the level of antibodies was significantly lower for this new variant
56 of concern as compared to delta and ancestral virus.

57

58 **METHODS**

59 **Human Ethics**

60 The study was approved by the Institutional ethics committees for human research at
61 ESIC Hospital and Medical College and THSTI. Informed consent was obtained from all
62 the participants.

63

64 **Human Samples**

65 *BBV152 cohort*: An informed consent was obtained in person from each participant before
66 they were being recruited in this study at the ESIC Medical College & Hospital, Faridabad
67 between May – August 2021. All adults of > 18 years of age who came for the first dose
68 of vaccine were eligible to participate in this study including those who had recovered
69 from the COVID-19 in the recent past. In addition, participants were requested to provide
70 any history related to COVID-19 infection. Blood samples of the participants were
71 collected in anti-coagulant free vacutainers with the help of a professional phlebotomist
72 and stored at 2 - 8 °C. First blood sample (5 ml) was collected on day 1 prior to the
73 administration of the first dose of the vaccine. Second blood sample (5 ml) was collected
74 during the follow-up visit before the administration of the second dose of the vaccine.

75

76 **Cells**

77 Vero E6 cells were obtained from European Collection of Authenticated Cell Cultures and
78 maintained in Minimal essential medium (MEM) (Gibco) supplemented with 10% heat-
79 inactivated fetal bovine serum (FBS), 100U of penicillin and 100 µg of streptomycin and
80 L-glutamine (PSG) (Gibco), 1X non-essential amino acid mix (NEAA) (Gibco), 25 mM
81 HEPES in 5% CO₂ incubator. Calu-3 cells (Human lung epithelial cells derived from
82 adenocarcinoma: ATCC-HTB-55) were maintained in Dulbecco's minimal essential
83 medium (DMEM) (HiMedia) supplemented with 10% heat-inactivated fetal bovine serum
84 (FBS), 100U of penicillin and 100 µg of streptomycin and L-glutamine (PSG) (Gibco), 1X
85 non-essential amino acid (NEAA) (Gibco),

86

87 **Viruses**

88 SARS-CoV-2 to B.6 and delta lineage virus isolation has been described earlier³⁻⁵. SARS-
89 CoV-2 Omicron isolate (sub-lineage BA.1) was obtained from Leo Poon⁶. SARS-CoV-2
90 variants were propagated in Vero E6 cells or Calu-3 cells⁷ and virus passaging was limited
91 to four passages. All virus stocks used in this study was verified by whole genome
92 sequencing using total RNA sample of the culture on Nanopore sequencing platform as
93 described previously to confirm the variant⁸.

94

95 **Quantitative Nucleoprotein ELISA**

96 The bacterial expression plasmid pET-28a(+) containing the codon optimized
97 nucleocapsid (N) gene from severe acute respiratory syndrome-related coronavirus 2
98 (SARS-CoV-2), Wuhan-Hu-1 (GenBank: MN908947) having N-terminal hexa-histidine
99 affinity purification tag was requested from BEI resources (NR-53507). His-tagged N
100 protein was purified by Ni-NTA chromatography as per previous report⁹. 96-well
101 MaxiSorp ELISA plates (Nunc) were coated with 1 µg/mL purified N protein diluted in 1X
102 PBS pH 7.4 and the plates were incubated for 1 h at room temperature (RT). Serum
103 samples were inactivated using Triton X-100 (Sigma) to a final concentration of 1 % at
104 RT for 1 h. The serum samples were two-fold serially diluted starting from 1:100 to 1:
105 6400 and 100 µl/well was added to the antigen-coated plate. After 30 min at room
106 temperature, the plate was washed using 1X PBST (phosphate-buffered saline with 0.1
107 % Tween 20). After washing, 50 µl/well HRP-conjugated anti-human IgG was added and
108 incubated at room temperature for 30 min. 100 µl/well of TMB substrate was added for

109 10 min and the reaction was terminated using 1M H₂SO₄ as stop solution. The intensity
110 of the color was quantified by measuring absorbance in a microplate reader at 450 nm
111 with 630 nm as reference wavelength. Antibody concentrations were calculated for each
112 sample dilution by interpolation of the OD values on the 4-parameter logistic (4-PL)
113 standard curve from in-house reference control (calibrated as a secondary standard using
114 WHO reference standard reagent (20/130)) and adjusted according to their corresponding
115 dilution factor using Gen5 software. The assay has a limit of quantitation of 3 binding
116 antibody units/mL (BAU/mL). This assay has been validated in-house and accredited
117 under ISO17025:2017 standard.

118

119 **Quantitative RBD ELISA**

120 Recombinant spike protein receptor binding domain (RBD) ELISA was performed as
121 described earlier^{4,10}. Recombinant spike protein Receptor Binding Domain (RBD) antigen
122 of SARS-CoV-2 were coated onto 96-well polystyrene plate (0.1µg/well) and incubate
123 coated plate at 4°C for 18-22 hours. Antigen-coated plates were washed with wash buffer
124 and incubated by adding 200 µl of blocking buffer (5% non-fat dry milk powder in PBST).
125 Serum samples were inactivated by adding 10 µl of 10% Triton X-100 in 90 µl serum to
126 obtain a final concentration of 1% Triton X-100. Samples were gently mixed and
127 incubated at room temperature for 1 hour. After washing the plate with wash buffer, 100
128 µl of diluted serum (1:50-1:6400 diluted in blocking buffer) was added to each well and
129 incubated at RT (23±2°C) for 30 ± 10 min. Substrate was added and OD was recorded
130 and data was analyzed as described in the previous section. The assay has a limit of

131 quantitation of 12 binding antibody units/mL (BAU/mL). This assay has been validated in-
132 house and accredited under ISO17025:2017 standard.

133

134 **Virus microneutralization assay**

135 Virus microneutralization assay by focus reduction neutralization titer assay using
136 indicating virus isolates was performed as described earlier with minor modifications in
137 omicron variant staining⁷. Briefly, serum samples were serially diluted from 1:20 to 1:640
138 and virus neutralization was tested in Vero E6 cells. Cells were incubated for 24 hours for
139 ancestral (B.6) and Delta (B.1.617.2) variants and for 32 hours for Omicron (B.1.1.529)
140 variant. After incubation, cells were fixed with formaldehyde solution and then stained
141 with anti-spike RBD rabbit polyclonal antibody at 1:2000 dilution (Sino Biologicals, Cat.
142 No. 40592-T62) for 1 h, followed by HRP-conjugated anti-rabbit antibody at 1:4000
143 dilution (Invitrogen, Cat. No. G-21234) for 1 h. For Omicron isolate, incubation was
144 extended to 32 h and a 1:1000 dilution of anti-nucleocapsid primary antibody (Genscript,
145 Cat. No. A02048-1) and 1:500 dilution of HRP-conjugated goat anti-mouse IgG secondary
146 antibody (Invitrogen, Cat. No. A16072) was used for staining. Cells were washed with
147 PBS and incubated with TrueBlue substrate (KPL inc, USA, Cat. No. 5510-0030) for 10
148 minutes and washed with sterile MilliQ water. Microplaques developed after staining were
149 quantified by AID iSPOT reader (AID GmbH, Strassberg, Germany). The raw data
150 generated from the AID iSpot Analyser in a 96-well format is pasted in a pre-defined
151 protocol template for calculation of FRNT₅₀ by using log₁₀ transformed dilution value and
152 neutralization percentages in an XY format. The Point-to-Point curve fit using a linear
153 equation to fit each pair of data points was used to calculate the FRNT₅₀ value. 50%

154 neutralization values were calculated using SoftMax Pro GxP software v7.7.1 (Molecular
155 Devices).

156

157 **Statistical analysis**

158 Data was analysed and final graphs were prepared using GraphPad Prism (Version 9)
159 software. Statistical significance was estimated by two-tailed, non-parametric Mann-
160 Whitney test or Wilcoxon signed rank test as indicated.

161

162 **RESULTS**

163 We collected baseline blood sample at the time of vaccination and a follow-up sample
164 four weeks later, before the second dose in the months of June-July 2021. A total of 94
165 (37 females) subjects were enrolled. Median age of the subjects was 31.5 yrs (range: 18-
166 67 yrs). Sixty-seven of 94 (71.3%) subjects were positive in a quantitative RBD-ELISA in
167 the baseline sample. Four samples were indeterminate. We also measured the levels of
168 nucleocapsid (N) antibodies by quantitative ELISA. Fifty five of the 94 (58.5%) samples
169 were positive for N antibodies suggesting exposure in the second wave. After one dose
170 of vaccination, positivity in RBD-ELISA increased to Eighty four of 94 samples (89.4%)
171 and for N-ELISA 79 out of 94 samples (84%) were positive. The GMT of RBD antibodies
172 increased significantly from 109 (95% CI: 76, 156) to 206 (95% CI: 163, 260) in baseline
173 seropositive (Figure 1A) subjects, however, the increase in the GMT of N antibodies was
174 from 18 (95% CI: 12, 25) to 25 (95% CI: 20, 31) which was not significant (Figure 1B).

175 We next measured the virus neutralizing antibody titers against the SARS-CoV-2
176 B.6 lineage virus from 2020⁴ (designated as WT) and B.1.617.2 (Delta variant) isolates in

177 both the baseline and post-single dose vaccination samples by focus reduction
178 neutralization titer (FRNT) assay. Overall GMT of neutralizing antibodies increased after
179 one dose of BBV152 vaccination for both WT virus and delta variant (Table 1). Both RBD
180 and N antibody levels correlated with neutralization titers against the delta variant after
181 the first dose (Supplementary Figure S1). The FRNT data were further analyzed based
182 on the seropositivity status at baseline in RBD-ELISA and we found that one dose of
183 BBV152 vaccine led to significant increase in GMT for neutralizing antibodies against the
184 WT virus (Table 1 and Figure 1C). However, the GMT for delta variant showed a marginal
185 and insignificant increase from 531.9 (95% CI: 371.6, 761.2) to 783.2 (95% CI: 624.8,
186 981.7) in the RBD-ELISA positive subgroup at baseline (Table 1 and Figure 1C). Twenty-
187 two out of 23 baseline RBD-ELISA negative samples showed the presence of neutralizing
188 antibodies for WT and delta variant in FRNT assay, however, the levels of these
189 antibodies were about 7-8 fold lower than that in the ELISA-positive samples (Table 1)
190 suggesting that the antibody levels were below the level of detection of ELISA and these
191 are not seronegative subjects. In samples collected from baseline RBD-ELISA negative
192 participants, the GMT of antibodies against both the WT and B.1.617.2 lineage viruses
193 increased significantly after receiving the first dose of the vaccine (Table 1 and Figure
194 1D). Overall, we observed that samples with $FRNT_{50} > 1000$ failed to show any induction
195 in antibodies after the first dose. We observed a clear negative correlation between the
196 baseline $FRNT_{50}$ titer for delta variant and the fold change in titer values after a single
197 dose of vaccination (Figure 1E).

198 While this study was in progress, omicron (B.1.1.529) emerged as a variant of
199 concern and antibodies from most vaccines showed reduced efficiency in neutralizing this

200 variant^{7,11,12}. We randomly selected 55 paired samples (which had a FRNT₅₀ value for the
201 delta variant) to test for their ability to neutralize the omicron variant. Only twenty out of
202 55 baseline samples had detectable levels of neutralizing antibodies against omicron. By
203 assigning a FRNT₅₀ value of 10 for the samples which had no detectable levels of
204 antibodies in the starting dilution (1:20) of the assay, we obtained a GMT of 22 (95% CI:
205 16, 31) for these 55 samples. This value was 18-fold lower than the GMT of delta variant
206 which was 404 (95% CI: 248, 658). After a single dose of BBV152, the number of samples
207 positive for neutralizing antibodies against omicron increased to thirty six out of 55
208 subjects with a significant increase in GMT ($p = 0.0011$) to 52 (95% CI: 36, 75), however,
209 this was still 15-fold lower than the GMT for delta variant which was 784 (95% CI: 575,
210 1068) (Figure 1F and 1G). Whether the modest but significant boosting observed for
211 omicron by BBV152 vaccination in seropositive individuals is protective or not warrants
212 further studies from the ongoing booster vaccination campaign across the country.

213 Vaccination in early convalescent individuals led to poorer boosting as observed
214 in other studies¹³⁻¹⁵. In naturally infected individuals, boosting after six months is predicted
215 to increase the vaccine effectiveness against variants of concern¹⁶. We were not able to
216 ascertain the exact date of past infection in most of these individuals which is not unusual
217 as most COVID-19 infections are asymptomatic or mild and are not diagnosed.
218 Nucleocapsid antibodies are known to decay with a half-life of 68 days¹⁷ and 59% of our
219 study participants were positive for N antibodies suggesting that they could have been
220 infected with SARS-CoV-2 within the past 6-8 months. Therefore, we cannot rule out the
221 possibility that some of the subjects with high antibody titers were in their early
222 convalescence and therefore, the boosting effect may not have been significant due to

223 energy of the immune system as has been observed in other studies¹⁸. Antibody boosting
224 correlated negatively with the levels of pre-existing antibodies which indicates that a
225 strategy is needed to prioritize high-risk individuals based on their antibody levels for
226 booster vaccination. Nevertheless, the level of neutralizing antibodies for omicron variant
227 after boosting in both seropositive and seronegative individuals remained much lower
228 compared to the ancestral virus or the delta variant which is consistent with recent reports
229 for CoronaVac, an inactivated vaccine¹⁹. However, the participants of our study were all
230 non-vaccinated individuals and we cannot rule out the possibility that vaccination of these
231 individuals after further reduction in antibody titers would have induced a better antibody
232 response. It has been estimated that neutralizing antibodies are a good correlate of
233 protection and contribute to about 60% of the protective efficacy of a vaccine which
234 indicates that the cellular responses play a critical synergistic role along with antibodies
235 in mediating protection from SARS-CoV-2 VoCs^{4,5,16}. Some of the recent studies have
236 also shown that heterologous boosting mounts a robust immune response to VoCs²⁰. As
237 many new vaccines are likely to be licensed in the coming months in India, more studies
238 are required to measure the efficacy of homologous vs heterologous boosting against
239 new variants of concern.

240

241 **Data availability**

242 All the data are presented in this manuscript. Detailed Methods are available as online
243 methods.

244

245 **ACKNOWLEDGEMENTS**

246 We thank all the members of the bioassay lab for technical support. We thank Neha Garg
247 and Shamsher Singh for data management. We thank all the participants who consented
248 to enrol into the study.

249

250 **AUTHOR CONTRIBUTIONS**

251 JS, HS, BS, AA, and PS performed experiments and analyzed the data. SD and AKP
252 coordinated the study at clinical site, generated all the clinical site data and contributed
253 reagents. RP sequenced the virus isolates and analyzed the data. RL provided critical
254 inputs in experimental design, data analysis and writing the manuscript. GRM and AKP
255 conceived the study, designed the experiments and analyzed the data. GRM wrote the
256 manuscript. All authors have reviewed and approved the final version of the manuscript.

257

258 **FUNDING INFORMATION**

259 This work was supported by the Department of Biotechnology (DBT) through IndCEPI
260 Mission (BT/MB/CEPI/2016), Translational Research Program
261 (BT/PR30159/MED/15/188/2018) and Global Immunology and Immune Sequencing for
262 Epidemic Response (INV-030592). The funders had no role in study design, data
263 collection and interpretation or the decision to submit the work for publication.

264

265 **CONFLICT OF INTEREST STATEMENT**

266 The authors have declared that no conflict of interest exists.

267

268

269 **Table 1: Virus neutralization titers post single-dose of BBV152 vaccination based**
 270 **on RBD-ELISA positivity**

271

	Geometric Mean FRNT50 (95% CI)					
Sampling time	Baseline WT (A)	One dose WT (B)	P value comparing the titers within each group; before and after 1 dose of vaccine (A vs B) (Wilcoxon signed rank test)	Baseline B.1.617.2 (C)	One dose B.1.617.2 (D)	P value comparing the titers within each group; before and after 1 dose of vaccine (C vs D) (Wilcoxon signed rank test)
All (n=94)	108.6 (81.3 – 145.1)	256.4 (196.1 – 335.3)	<0.0001	291.4 (209.6 – 405.0)	508.1 (398.9 –647.2)	0.0126
Groups based on RBD ELISA results						
1. RBD- positive at baseline (n=67)	182.8 (133.6 – 250.0)	422.2 (340.5 – 523.5)	0.0001	531.9 (371.6 – 761.2)	783.2 (624.8 – 981.7)	0.448
2. RBD- Negative at baseline (n=23)	26.50 (19.8 – 35.5)	57.32 (33.0 – 99.6)	0.0033	63.94 (46.4 – 88.1)	146.6 (95.7 – 224.7)	0.0002
P value comparing the titers between 2 groups based on RBD ELISA (using Wilcoxon rank sum test)	<0.0001	<0.0001		<0.0001	<0.0001	

272 Comparison of titers at baseline and 3-4 weeks after 1st dose was performed using Wilcoxon
 273 signed rank test. Comparison of titers between the groups (based on RBD ELISA results) was
 274 done using Wilcoxon rank sum test.

275

276 **REFERENCES**

- 277 1. Jahan, N., *et al.* Seroprevalence of IgG antibodies against SARS-CoV-2 in India,
278 March 2020 to August 2021: a systematic review and meta-analysis. *Int J Infect*
279 *Dis* **116**, 59-67 (2021).
- 280 2. Sharma, P., *et al.* SARS-CoV-2 seroprevalence in Delhi, India - September-
281 October 2021 – a population based seroepidemiological study. *medRxiv*,
282 2021.2012.2028.21268451 (2021).
- 283 3. Anantharaj, A., *et al.* Kinetics of viral load, immunological mediators and
284 characterization of a SARS-CoV-2 isolate in mild COVID-19 patients during acute
285 phase of infection. *medRxiv*, 2020.2011.2005.20226621 (2020).
- 286 4. Anantharaj, A., *et al.* Resolution of viral load in mild COVID-19 patients is
287 associated with both innate and adaptive immune responses. *Journal of Clinical*
288 *Virology* **146**, 105060 (2022).
- 289 5. Thiruvengadam, R., *et al.* Effectiveness of ChAdOx1 nCoV-19 vaccine against
290 SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-
291 negative, case-control study and a mechanistic study of post-vaccination immune
292 responses. *The Lancet Infectious Diseases* (2021).
- 293 6. Gu, H., *et al.* Probable Transmission of SARS-CoV-2 Omicron Variant in
294 Quarantine Hotel, Hong Kong, China, November 2021. *Emerg Infect Dis* **28**(2021).
- 295 7. Medigeshi, G., *et al.* Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by
296 Antibodies induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine
297 (Hybrid Immunity) post 6-months. *medRxiv*, 2022.2001.2004.22268747 (2022).

- 298 8. Kumar, P., *et al.* Integrated genomic view of SARS-CoV-2 in India. *Wellcome Open*
299 *Res* **5**, 184 (2020).
- 300 9. Cubuk, J., *et al.* The SARS-CoV-2 nucleocapsid protein is dynamic, disordered,
301 and phase separates with RNA. *Nat Commun* **12**, 1936 (2021).
- 302 10. Stadlbauer, D., *et al.* SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol
303 for a Serological Assay, Antigen Production, and Test Setup. *Curr Protoc Microbiol*
304 **57**, e100 (2020).
- 305 11. Cele, S., *et al.* SARS-CoV-2 Omicron has extensive but incomplete escape of
306 Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. *medRxiv*
307 (2021).
- 308 12. Dejnirattisai, W., *et al.* Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529
309 variant by post-immunisation serum. *Lancet* (2021).
- 310 13. Edara, V.V., *et al.* Infection and Vaccine-Induced Neutralizing-Antibody
311 Responses to the SARS-CoV-2 B.1.617 Variants. *N Engl J Med* **385**, 664-666
312 (2021).
- 313 14. Stamatatos, L., *et al.* mRNA vaccination boosts cross-variant neutralizing
314 antibodies elicited by SARS-CoV-2 infection. *Science* (2021).
- 315 15. Leier, H.C., *et al.* Previously infected vaccinees broadly neutralize SARS-CoV-2
316 variants. *medRxiv*, 2021.2004.2025.21256049 (2021).
- 317 16. Cromer, D., *et al.* Neutralising antibody titres as predictors of protection against
318 SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *Lancet Microbe*
319 **3**, e52-e61 (2022).

- 320 17. Dan, J.M., *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8
321 months after infection. *Science* **371**(2021).
- 322 18. Kannian, P., Mahanathi, P., Ashwini, V. & Kumarasamy, N. Booster and anergic
323 effects of the Covishield vaccine among healthcare workers in South India.
324 *medRxiv*, 2021.2008.2004.21261601 (2021).
- 325 19. Cheng, S.M.S., *et al.* Neutralizing antibodies against the SARS-CoV-2 Omicron
326 variant following homologous and heterologous CoronaVac or BNT162b2
327 vaccination. *Nature Medicine* (2022).
- 328 20. Angkasekwinai, N., *et al.* The immunogenicity against variants of concern and
329 reactogenicity of four COVID-19 booster vaccinations following CoronaVac or
330 ChAdOx1 nCoV-19 primary series. *medRxiv*, 2021.2011.2029.21266947 (2022).

331

332 **FIGURE LEGEND**

333 **Figure 1: Antibody boosting after a single dose of BBV152 vaccination.** Serum levels
334 of antibodies against (A) SARS-CoV-2 RBD and (B) N protein was estimated by
335 quantitative ELISA after a single dose of BBV152 vaccine in baseline and post-
336 vaccination samples collected 3-4 weeks later. Data was expressed as Binding Antibody
337 Units (BAU)/ml (international units). (C) FRNT₅₀ titers in RBD ELISA-positive samples for
338 the ancestral B.6 lineage (WT) and the delta variant (B1.617.2) in baseline and post-
339 single dose vaccination samples. (D) FRNT₅₀ titers in RBD ELISA-negative samples for
340 the ancestral B.6 lineage (WT) and the delta variant (B1.617.2) in baseline and post-
341 single dose vaccination samples. (E) Spearman correlation (r) between baseline FRNT₅₀
342 titers and fold-change observed after single-dose of BBV152. (F and G) FRNT₅₀ titers for

343 the delta variant (B1.617.2) and omicron (1.1.529) variant in baseline and post-single
344 dose vaccination samples. LLOQ: Lower limit of quantitation of the assay. Two-tailed t
345 test P values are indicated by - * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$; ns -
346 not significant.

347

Figure 1

